Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed ...

VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory ...

Genialis, the therapeutic intelligence company, today announced Genialis™ BioBridge to help pharmaceutical sponsors translate clinical results generated in Chinese patient populations into ...

Purdue researchers developed a mass spectrometry platform that accelerates cancer drug discovery by integrating synthesis, ...

Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug ...

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.

Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from breaking when cells copy damaged genetic material, a discovery that could ...

A new study has identified a more precise and effective way to prevent cancer from spreading to the brain. The paper, ...